Mixed lymphocyte islet culture (MLIC) and its use in manipulation of human islet alloimmunogenicity by Ulrichs, Karin & Müller-Ruchholtz, W.
• 
123 
Mixed Lymphocyte Islet Culture (MLIC) and its Use in 
Manipulation of Human Islet Alloimmunogenicity 
Karin Ulrichs and W. Muller-Ruchholtz 
Department of Immunology, Medical School of the University, Kiel, Germany 
Introduction 
Human islets have been transplanted clinically to 
reverse diabetes, though with poor overall success 
(reviewed in Hering, Bretzel and Federlin 1988). In-
ferring from experimental islet transplantation, it is 
presently suggested that methods for separating the 
endocrine from the exocrine pancreas portion and/or 
serological tissue manipulations prior to islet trans-
plantation should be sought in order to reduce the 
graft's immunogenicity and thus improve the clinical 
results (Gray and Morris 1987; Gray 1989). In addi-
tion to physical separation procedures, anti-MHC 
class II (pre )treatment of the graft appears to remain 
an attractive concept, though thus far insufficiently 
controlled and with controversial success in vivo 
(Faustman, Hauptfeld, Lacy and Davie 1981; Reece-
Smith, McShane and Morris 1984). This situation 
calls for suitable in vitro test systems to better define 
manipulative conditions and to help in predicting the 
in vivo outcome. 
One· approach toward prediCting the result of an in 
vitro manipulation prior to islet transplantation ap-
pears to be the mixed lymphocyte islet culture 
(MLIC) , derived from the one-way mixed lympho-
cyte culture (MLC) which has been well established 
to serve this purpose, e.g., in clinical bone marrow 
transplantation. A few attempts using isolated islets 
of Langerhans as stimulator population have been 
reported for the canine (Roth, Russell, Fuller, Kyri-
akides, Mintz and Miller 1984), and more recently 
also for the mouse (Stock, Asher, Kaufmann and 
Sutherland 1987) and the rat (Shizuru, Ramak-
rishnan, Hunt, Merrell and Fathman 1986; Lloyd, 
Cotler, Letai, Stuart and Thistletwaite 1989) systems. 
However, no data are available thus far for the 
human system using collagenase-digested islets as 
stimulator cells. Thus, it was our aim to adapt the 
MLIC to human islets and to perform a variety of 
anti-MHC class II (pre)treatment protocols. 
Materials and Methods 
Human islet isolation 
Islets were isolated from HLA-typed cadaver donor 
pancreata with the collagenase/Ficoll technique of 
Gray, McShane and Morris (1984). In good concor-
dance with their observations, the final endocrine 
tissue content ranged between 10-40% with an islet 
size variation in the order of approx. 1:5. The viabil-
ity of the preparation was estimated with the trypan 
blue dye exclusion test and was usually >95%. Islets 
were then transferred into a freeze medium (10% 
dimethylsulfoxide, DMSO, 40% RPM! medium with 
5% fetal calf serum, PCS, 50% pure PCS), frozen at 
-80 ·C for 24 h, transferred to liquid nitrogen and 
stored until further use. 
Islet identification 
Isolated islets were identified from exocrine tissue 
debris with the help. of the zinc-specific dithizone 
(diphenylthiocarbazone, D1Z, Sigma Chemie, 
Munchen) staining technique (Latif, Noel and Alejan-
dro 1988). 
Complementary to the 10-40% endocrine tissue con-
tent, as evaluated with the D1Z staining technique, 
the exocrine tissue content comprised 90-60% of the 
unpurified islet preparations. For the experiments re-
ferred to in this study, the only preparations used for 
stimulator populations were those that had an ex-
ocrine content in the range of 60-75%, i.e., prepara-
tions and (see below). Preparation differed from the 
others in that the degree of enzymatic digestion was 
high, i.e., the islets were practically free of an exo-
crine rim (whereas the majority of the islets from the 
other 3 preparations were surrounded by an exocrine 
rim as a consequence of enzymatic underdigestion). 
Preparation of crude stimulator islets 
A crude stimulator islet preparation was obtained 
from the deep-frozen preparations mentioned above 
by quick thawing at 37 ·C and repeated washings at 
500 rpm/l 0 sec. The final pellet was resuspended 1:2 
in complete RPMI (10% human NB serum, 1 % 
penicillin/streptomycin and 1 % L-glutamin). Cell 
viability was estimated with the trypan blue dye ex-
clusion test and was >90%. Thereafter the crude islet 
preparation was gently treated with mitomycin C 
(Sigma chemie, Munchen; 12.5 Jlg mitomycin C in 1 
ml RPM! for about 1.000 islets, 20 min at 37 ·C in a 
water bath) to avoid proliferation of the nonhorrnonal 
cells. After careful washing, the crude preparation 
was diluted with complete RPM! until 100 J.Ll con-
tained approximately 40 islets. 
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Preparation of responder Iymphocytes 
Peripheral human blood lymphocytes were isolated 
from heparinized blood of HLA-typed healthy in-
dividuals by density gradient centrifugation. They 
were washed 3 x at 1.200 rpm in complete RPMI and 
used at a concentration of 107 cells/m!. 
Mixed Iymphocyte islet culture 
106 peripheral blood responder lymphocytes from 
healthy individuals in 1 00 ~ complete RPM! were 
co-cultured in quadruplicate with approximately 40 
crude stimulator islets in 100 ~ complete RPM! in a 
96-well microtiter culture plate/F-form (Greiner, 
Niirtingen) for 5 days at 37°C and 5% CO2 in air. 16 
h prior to cell harvesting at day +6, 1 mCi 3H-
methyl-thymidine was added to each culture. The 
HLA pattern of the stimulator islet donor and the 
corresponding responder lymphocyte donor are indi-
cated in Table 1. 
Table 1 HL pattern of stimulator islet donor (stim) and corre-
sponding responder Iymphocyte donor (resp). as used in 
MUC experiments. 
HLA pattern 
#10 stim: Al. A25. 88. DR3 
resp: A2. A26. 827. 838. DR5 
#15 stim: A24. - . 837. - . DRl 
resp: A2. All. 835. 851. DR4 
#17 stim: Al. A3. 844. - . DR7 
resp: Al. A3. 835. 837. DRl 
#18 stim: A2. A24. 87. 827. DR2 
resp: A2. All. 835. 851. DR4 
# = number of crude islet preparation as inducated in Mate-
rial and Methods 
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Inhibition of MUC by monoclonal MHC class 11 
antibodies r039 and 1 aB3 
MLIC inhibition experiments were performed with 
the two HLA-DR/DP-specific monoclonal antibodies 
(1'039 (clonab 39 from Biotest, Frankfurt) and laB3 
of our own production (Harpprecht 1990). Since 
both antibodies reacted identically in the various 
morphological and functional tests, they are referred 
to as anti-MHC class II antibodies. TU39 (ascites) 
was used diluted 1 :40 with phosphate-buffered saline 
(PBS), laB3 (culture supernatant) was used undi-
luted. For preincubation studies, either 5 x 107 re-
sponder lymphocytes or 1000 crude islets were in-
cubated with 1000 ~ anti-MHC II for 40 min/24 0c. 
Careful repeated washing ensured that no free anti-
body contaminated the culture medium. In another 
set of experiments 40 ml anti-MHC II were added 
permanently to the culture system. The anti-rat MHC 
class II specific monoclonal antibody MRC-OXI7 
(diluted 1:40 with PBS) was used as a specificity 
contro!. 
ReSUlts 
Variation of crude stimulator islet preparation 
To determine the number of crude islets required, 
increasing numbers, ranging from 5-50, of HLA-
mismatched crude stimulator islets (prep. #10, #17 or 
# 18) were added to 106 peripheral blood responder 
lymphocytes. Fig. 1 shows the result of this experi-
ment representatively with crude islet preparation 
# 10. Whereas 5 and 10 crude islets per well did not 
elicit a significant immune response beyond back-
ground reactivity (stimulator index, SI=O.O and 
0.24), a continuous increase occurred between 20 
and 40 crude islets (SI=3.0/20 is!.; SI=4.3/30 isl; 
SI=7.1/40 isl). With as many as 50 crude stimulator 
islets/well, however, 3H-thymidine uptake began to 
decrease again (SI=5.6). Crude islet preparations #17 
--.I __ 
Fig. 1 Human mixed Iym-
phocyte islet culture 
(MUC) experiments (exp) 
with varying numbers (5-
.I__ 50) of HLA-mismatched. 
mitomycin C-pretreated. 
crude islet preparations 
(prep. #10) acting as stimu-
lator cells to 106 responder 
Iymphocytes; controls: re-
sponder Iymphocytes 
(resp) + medium and 
---I 
crude stimulator islets 
(stim) + medium; no. of 
identical experiments = 4. 
resp_ stim. exp-5 exp-10 exp-20 exp-30 exp-40 exp-50 
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and #18 reacted in a similar fashion. 
Inhibition of MUC response by MHC class 11 monoclo-
nal antibodies 
Having shown that the MLIC test system allowed us 
to analyze the immunogenicity of the crude human 
islet graft in vitro, the major manipulative effort to 
diminish immunogenicity consisted in treating the 
MLIC components with MHC class II monoclonal 
antibodies. Four different approaches were chosen, 
using crude islet preparations and (a) pretreatment 
of the stimulators, (b) pretreatment of the responders, 
(c) pretreatment of both stimulators and responders 
and (d) permanent presence of the antibody during 
the culture period. Repeated and thorough washings 
after the preincubation period ensured that no free 
antibody contaminated the medium during the co-
culture period. The results of this experiment are 
shown in Fig. 2A representatively for crude islet 
preparation #10. Of the four different approaches, (a) 
had the poorest effect, showing only 58% inhibition 
(compare column 5 with col. 3). Comparatively more 
effective was approach (b). pretreatment of the re-
sponder cells, with 96% inhibition (compare col. 4 
with col. 3). As to be expected, approach (c), pre-
treatment of both responder cells and crude stimula-
tor islets, led to almost identical results, namely 97% 
inhibition (compare col. 6 with col. 3). Similarly ef-
fective was approach (d) with 100% inhibition when 
the antibody remained within the culture system until 
5 6 7 
cell harvesting (compare col. 7 with col. 3). Experi-
ments with crude islet preparation led to nearly iden-
tical results. 
To prove the specificity of the inhibition, a control 
experiment was carried out with the HLA-DP/DR 
non-crossreactive mouse anti-rat MHC class II anti-
body MRC-OX17. As shown in Fig. 2B, of all treat-
ment protocols (coL 4-7), only preincubation of the 
crude stimulator islets with MRC-OX 17 had a mild, 
but nonsignificant inhibitory effect(col. 5) which re-
mained unidentifiable when islets and responder 
cells were pretreated at the same time. 
Influence of the exocrine tissue content on islet 
immunogenicity 
Since the previous experiments were performed with 
crude islet preparations, i.e., islets contaminated by 
60-75% of exocrine tissue fragments, either free or 
still attached to the islets as a consequence of enzy-
matic underdigestion, it was of particular interest to 
analyze the stimulator capacity of purified islets. For 
this purpose crude islet preparation was useful as the 
stimulator population. Purified islets were obtained 
by handpicking from the crude islet preparation de-
scribed in Material and Methods, a procedure accep-
table for experimental, though not for clinical pur-
poses. The results of this study with 40 islets per 
experiment are demonstrated in Fig. 3. Compared to 
the unpurified islets (Gray 1989; Faustman et al. 
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1981; Reece-Smith et al. 1984), purified islets (Roth 
et al. 1984; Stock et al. 1987; Shizuru et al. 1986) are 
significantly less immunogenic and, without further 
treatment, elicit only 32% of the original immune 
response (compare Gray 1989 with Roth et al. 1984). 
In other words, with regard 10 islet preparation the 
exocrine tissue portion contributes 68% of the islet 
immunogenicity. Having thus decreased islet im-
munogenicity by a separation procedure in a first 
step, antibody pretreatment (anti-MHC class ID of 
the stimulator islets now reduces it 10 background 
reactivity (compare Faustman et al. 1981 with Stock 
et al. 1987). As 10 be expected from the previous 
experiments shown in Fig. 2, permanent presence of 
the antibody in the culture medium has a similar ef-
fect on both types of incubation protocols since reac-
tivity was already at background when the unpurified 
preparation was used (compare Reece-Smith et al. 
1984 with Shizuru et al. 1986). 
Discussion 
To summarize the results, we were able 10 show that 
the immunogenicity of isolated crude human islet 
preparations (a) can be effectively measured in vitro 
with the MLIC and (b) can be inhibited by MHC 
class II antibody treatment protocols in connection 
with physical purification procedures. It may be 
pointed out that we were interested in the immuno-
genicity of the islet preparations under study rather 
than endocrinological parameters. 
Studies with the MLIC, using normal crude human 
islet preparations, are reported here for the first time. 
However, the modification of the MLC into MLIC in 
the human system was suggested by previous experi-
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Fig. 3 MUC with unpurified 
(column 3-5) and purified 
(col. 6-8) stimulator islets 
of crude preparation #15. 
Purification was performed 
by additional handpicking. 
Col. 1, responder Iympho-
cytes + medium; col. 2, 
crude or purified stimulator 
islets + medium; col. 3 and 
6, uninhibited allogeneic re-
sponse; col. 4 and 7, pre-
treatment of crude or 
purified stimulator islets 
with anti HLA-DRlDP mon-
oclonal antibody; col. 5 
and 8, permanent pres-
ence of the antibody during 
culture period. 
ments by other authors with canine, rat and mouse 
islets (Roth et al. 1984; Stock et al. 1987; Shizuru et 
al. 1986; Lloyd et al. 1989) as well as our own 
successful trials with rat islets (data under publica-
tion). But, unlike rodent islets, human islets are diffi-
cult to identify within a pancreas digest preparation. 
Therefore, the exact numbers of crude stimulator is-
lets and, correspondingly, the immune response per 
well of the microtiter plate varied greatly and led to 
unsatisfactory results in earlier trials. This problem 
was easily solved with the D1Z staining technique, 
which is islet-specific because of the Zinc content of 
islet cells. It is a simple technique, can be applied to 
islet preparations in vitro, and apparently is not spe-
cies-restricted, as similarly positive tests with human, 
rat and mouse islets show (Latif et al. 1988 and un-
published data from our laboratory). Thus, the im-
munogenicity of defined crude stimulator islet prepa-
rations can now be investigated. 
The optimum number of about 40 islets in a crude 
stimulator preparation per well remains clearly 
below the approximately 50-100 islets used for 
canine and rodent MLIC (Roth et al. 1984; Stock et 
al. 1987; Shizuru et al. 1986; Lloyd et al. 1989 and 
our own observations with rats). This may be ex-
plained by the fact that, different from handpicked 
well-digested animal stimulator islets, human islet 
preparations are still contaminated by exocrine tissue 
components which usually are transferred into the 
. wells along with the islets and, according to the re-
sults reponed in Fig. 3, contribute greatly to islet 
immunogenicity (Gray 1989). In this context it may 
be mentioned that we know from immunohistologi-
cal studies (manuscript in preparation) that the exo-
• 
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crine tissue fragments contain many lll...A-DR/DP-
positive cells, far more than pure islets. Our present 
conclusion is that the immunogenicity of viable islet 
preparations decreases with increasing purity. 
Even with improvements in the purification proce-
dures to remove free exocrine tissue debris from 
crude islet digests, as they are presently under way 
(Ricordi, Lacy and Scharp 1989; Warnock. Ellis. 
Cattral, Untch. Kneteman and Rajotte 1989; Winoto-
Morbach, Ulrichs. Leyhausen and Muller-Ruchholtz 
1989), the immunogenicity of the islet graft is still 
greatly determined by the extent of the exocrine rim 
around underdigested islets. Therefore manipulation 
of islet immunogenicity with MHC class II antibo-
dies appears to be an attractive, and, as our results 
suggest, successful concept for reducing the effect of 
present methodological shortcomings. Fig. 3 clearly 
indicates this, by showing a strong reduction or even 
abrogation of the allostimulatory capacity, depending 
on the kind of human islet preparation, following 
preincubation in such antibodies. This is in line with 
rat MLIC experiments with purified islets which 
show a complete reduction of aIloimmunogenicity, 
leaving the hormone-secreting islet cells unaffected, 
when stimulator islets were pretreated with anti-la 
immunotoxin (Shizuru et al. 1986) or MHC class 11 
antibodies and rabbit complement (Lloyd et al. 
1989). How far this holds for in vivo conditions re-
mains to be studied. It may well be envisaged that 
the latter require additional immunosuppressive 
treatment. Even so, from the in vitro studies we can 
conclude that a substantial decrease in graft immuno-
genicity should greatly facilitate graft acceptance and 
survival. 
Acknowledgements 
The authors wish to express their gratitude to Ms. M. 
Bartels and Mrs. M. v. Pein-Bohin for excellent tech-
nical assistance. Cadaver donor pancreata were pro-
vided by the transplantation team of the Dept. of 
General Surgery (Head: Prof. Dr. H. Hamelmann) 
whose excellent cooperation was essential for this 
work. The authors also wish to acknowledge the help 
of members of the Dept. of Immunology: Dr. E. 
Westphal and his staff, who performed the HLA-typ-
ing, and Dr. J. Harpprecht who produced and pro-
vided us with the lAb3 antibody. 
Karin Ulrichs and W. MOller-Ruchholtz 
Abbreviations 
DMSO = dimethylsulfoxide 
DTZ = diphenylthiocarbazone 
FCS = fetal calf serum 
RPMI = cell culture medium 
MLC = mixed lymphocyte culture 
MLIC = mixed lymphocyte islet culture 
References 
127 
Faustman, D., V. Hauptfeld, P. E. Lacy, J. Davie: Prolongation of 
murine islet allograft survival by pretreatment of islets with 
antibody directed to la detenninants. Proc. Nat!. Acad. Sci. 
USA 78: 515Cr5159 (1981) 
Gray, D. W. R., P. McShane, P. J. Morris: A method for isolation 
of islets of Langerhans from the human pancreas. Diabetes 33: 
1055-1061 (1984) 
Gray, D. W. R., P. J. Morris: Developments in isolated pancreatic 
islet transplantation. Transplantation 43: 321-331 (1987) 
Gray, D. W. R.: The role of exocrine tissue in pancreatic islet 
transplantation. Transplant. Int. 2: 41-45 (1989) 
Harpprecht, J.: Untersuchungen an Histokompatibilitiitsantigenen 
mit Hilfe monoklonaler Antikorper. Inaugural-Dissertation der 
Math.-Nat. Fakultiit zu Kiel . 
Hering, B. J., R. G. Bretzel, K. Federlin: Current status of clinical 
islet transplantation. Honn. Metabol. Res. 20: 537-545 (1988) 
Latif, Z. A., J. Noel, R. Alejandro: A simple method of staining 
fresh and cultured islets. Transplantation 45: 827-830 (1988) 
Lloyd, D. M., S. J. Coller, A. G. Letai, F. P Stuart, J. R. 
Thistletwaite Jr.: Pancreas-graft immunogenicity and pretreat-
ment with anti-class n monoclonal antibodies. Diabetes 38 
(Suppl. 1): 104-108 (1989) 
Reece-Smith, H., P. McShane, P. J. Morris: Effect of pretreatment 
of isolated adult islets with monoclonal antibody. Transplant. 
Proc. 16: 861-862 (1984) 
Ricordi, C., P. E. Lacy, D. W. Scharp: Automated islet isolation 
from human pancreas. Diabetes 38 (Suppl. 1): 140-142 (1989) 
Roth, D., T. Russell, L. Fuller, G. K. Kyriakides, D. Mintz, J. 
M iller: T -cell reactions versus kidney cells, islets of Langer-
hans, and non-T lymphocytes. Transplant. Proc. 16: 854-856 
(1984) 
Shizuru, J. A., S. Ramakrishnan, T. Hunt, R. C. Merrell, C. G. 
Fathman: Inhibition of rat mixed lymphocyte pancreatic islet 
cultures with anti-la immunotoxin. Transplantation 42: 660-
666 (1986) 
Stock, P., N. Asher, D. Kaujmann, D. Sutherland: Mixed islet-
lymphocyte culture as a model for pancreatic islet immuno-
genicity and cell-mediated immune injury. Transplant. Proc. 
19:4345-4346(1987) 
Warnock, G. L., D. K. Ellis, M. Cattral, D. Untch, N. M. 
Kneteman, R. V. Rajotte: Viable purified islets of Langerhans 
from collagenase-perfused human pancreas. Diabetes 38 
(Suppl. 1): 13Cr139 (1989) 
Winoto-Morbach, S., K. Ulrichs, q. Leyhausen, W. MiUler-
Ruchholtz: New principle for large scale preparation of 
purified human pancreas islets. Diabetes 38 (Suppl. 1): 14Cr 
149 (1989) 
Requests to: Dr. K. Ulrichs, Dept. Immunology, Medical School, Brunswikerstr. 4, D-2300 Kiel (Gennany) 
